Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07323095 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Evaluate the Efficacy and Safety of ABP-671 in Subjects With Chronic Kidney Disease and Hyperuricaemia

StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study sites: 9 to 10v3
  2. Start date: Feb 1, 2026 to Jun 30, 2026v2 Show 5 more changesShow less
    • Trial arms changed: 3 → 4
    • Enrollment target: 75 to 80
    • Study sites: 8 to 9
    • Interventions: ABP-671 Group (Drug), ABP-671 plus febuxostat Group 1 (Drug), ABP-671 plus febuxostat Group 2 (Drug) to ABP-671 Group (Drug), ABP-671 plus febuxostat Group 1 (Drug), ABP-671 plus febuxostat Group 2 (Drug), Placebo Group (Drug)
    • Secondary endpoints: details revised at 1 of 2 entries
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a phase 2, international, multicenter, randomized, double blind, placebo-controlled trial to evaluate the efficacy and safety of ABP-671 in subjects with CKD and hyperuricaemia, to preliminarily evaluate the efficacy of ABP-671 in the treatment of subjects with CKD and hyperuricemia, primary Efficacy Endpoint is change in UACR from baseline to Week 40
Trial Details
NCT Number NCT07323095
Lead Sponsor Atom Therapeutics Co., Ltd
Conditions
(from sponsor)		 Chronic Kidney Disease
Related terms Renal Insufficiency, Chronic
Enrollment 80 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov